Analysts expect Insmed Incorporated (NASDAQ:INSM) to report earnings per share (EPS) of ($1.13) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Insmed’s earnings, with the lowest EPS estimate coming in at ($1.16) and the highest estimate coming in at ($1.08). Insmed posted earnings of ($0.85) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 32.9%. The company is expected to issue its next quarterly earnings results on Friday, February 22nd.
According to Zacks, analysts expect that Insmed will report full year earnings of ($4.16) per share for the current year, with EPS estimates ranging from ($4.19) to ($4.10). For the next fiscal year, analysts anticipate that the company will report earnings of ($3.83) per share, with EPS estimates ranging from ($5.03) to ($2.79). Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Insmed.
Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.08).
A number of research analysts have recently issued reports on INSM shares. BidaskClub raised Insmed from a “strong sell” rating to a “sell” rating in a report on Thursday, September 27th. Morgan Stanley boosted their target price on Insmed from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, October 1st. Goldman Sachs Group set a $25.00 target price on Insmed and gave the stock a “hold” rating in a research report on Wednesday, September 19th. Citigroup reduced their price objective on Insmed from $29.00 to $22.00 and set a “neutral” rating on the stock in a research report on Tuesday, December 4th. Finally, Credit Suisse Group upped their price objective on Insmed from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, October 1st. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $30.43.
Shares of NASDAQ:INSM opened at $22.70 on Friday. The company has a debt-to-equity ratio of 1.07, a current ratio of 10.06 and a quick ratio of 10.06. The stock has a market cap of $1.59 billion, a P/E ratio of -7.85 and a beta of 1.93. Insmed has a 12-month low of $11.31 and a 12-month high of $32.07.
In other Insmed news, Director Melvin Md Sharoky bought 11,205 shares of the company’s stock in a transaction that occurred on Friday, November 9th. The stock was purchased at an average cost of $16.34 per share, for a total transaction of $183,089.70. Following the completion of the purchase, the director now owns 231,794 shares of the company’s stock, valued at approximately $3,787,513.96. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Roger Adsett bought 3,000 shares of the company’s stock in a transaction that occurred on Thursday, November 1st. The stock was acquired at an average price of $15.97 per share, with a total value of $47,910.00. Following the completion of the purchase, the insider now directly owns 18,594 shares of the company’s stock, valued at approximately $296,946.18. The disclosure for this purchase can be found here. Insiders bought 54,785 shares of company stock worth $871,726 over the last 90 days. Company insiders own 3.88% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the stock. NumerixS Investment Technologies Inc acquired a new stake in Insmed during the second quarter worth about $122,000. Pacer Advisors Inc. acquired a new stake in Insmed during the third quarter worth about $155,000. Dynamic Technology Lab Private Ltd acquired a new stake in Insmed during the second quarter worth about $200,000. Cubist Systematic Strategies LLC acquired a new stake in Insmed during the second quarter worth about $200,000. Finally, Essex Investment Management Co. LLC acquired a new stake in Insmed during the third quarter worth about $452,000.
Insmed Company Profile
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex.
See Also: What is the Consumer Price Index (CPI)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.